Lv51
1480 积分 2021-06-22 加入
Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial
1天前
待确认
Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61-20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial
1天前
已完结
Application of Neoadjuvant Docetaxel plus Cisplatin in Early-Stage Triple-Negative Breast Cancer (HELEN-001): Results from a Phase II Trial
1天前
已完结
JSKN003, a biparatopic HER2-targeting ADC, in heavily pretreated HER2-positive breast cancer: A pooled analysis of early-phase studies
8天前
已关闭
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer
11天前
已完结
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
11天前
已完结
Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study
11天前
已完结
Insights on Future Directions in Cancer Research from the 2025 AACR NextGen Stars
11天前
已完结
Axillary Surgery in Breast Cancer - Primary Results of the INSEMA Trial
2个月前
已完结
Breast Conservation Surgery and Mastectomy Have Similar Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From 1462 Patients on the Prospective, Randomized I-SPY2 Trial
2个月前
已完结
皖公网安备34019202002308
